ACTIVE

BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL

Export PDF

Financial year 2024 · closed on 31/12/2024

Net result

157 k €

+139.6% YoY

Gross margin

1,4 M €

-18.2% YoY

Equity

586,7 k €

+36.5% YoY

Workforce

14,6 ETP

-24.4% YoY

What does BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL do?

BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL is a Public limited company incorporated in 2001. Its registered office is in Gent. It employs on average 14,6 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0475.471.036

Incorporation

13/08/2001

Legal form

Public limited company

Registered office

Rijvisschestraat 118 box 1
9052 Gent · FlandreSee on map

Contributed capital

500 000,00 €

Latest accounts

31/12/2024

Average workforce

14,6 ETP

Joint committees (3)

226
330
33004

Signals

ProfitablePositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 18 financial years

	2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007
Income statement
Gross margin	1,4 M €	-18.2%	1,7 M €	-5.3%	1,8 M €	+74.9%	1 M €	-13.5%	1,2 M €	+109%	569,7 k €	-53.3%	1,2 M €	+23.0%	991,8 k €	+12.7%	879,7 k €	-22.7%	1,1 M €	+51.0%	753,2 k €	+12.9%	667,3 k €	-0.0%	667,6 k €	+2.7%	650,3 k €	+16.7%	557,3 k €	+6.2%	524,6 k €	+42.0%	369,4 k €	+3.8%	356 k €
EBITDA	273,3 k €	+25.8%	217,3 k €	-49.2%	427,5 k €	+557%	-93,6 k €	-164%	145,7 k €	+132%	-458,9 k €	-216%	396 k €	+155%	155 k €	+37.4%	112,8 k €	-18.6%	138,5 k €	+68.7%	82,1 k €	+13.7%	72,2 k €	-3.5%	74,9 k €	+8.7%	68,9 k €	-5.0%	72,5 k €	+0.4%	72,2 k €	+45.0%	49,8 k €	-34.6%	76,1 k €
Operating result	183,4 k €	+74.2%	105,3 k €	-67.2%	321,3 k €	+265%	-195,1 k €	-982%	22,1 k €	+104%	-575 k €	-293%	297,4 k €	+401%	59,4 k €	+93.9%	30,6 k €	-71.9%	109,2 k €	+78.2%	61,3 k €	+20.6%	50,8 k €	+4.7%	48,6 k €	+7.7%	45,1 k €	+8.7%	41,5 k €	-1.0%	41,9 k €	+105%	20,4 k €	-60.5%	51,7 k €
Net result	157 k €	+140%	65,5 k €	-77.5%	291,3 k €	+239%	-209,8 k €	-1671%	13,4 k €	+102%	-584,9 k €	-354%	230,7 k €	+818%	25,1 k €	+217%	-21,5 k €	-245%	14,8 k €	+34.3%	11 k €	+452%	2 k €	-3.3%	2,1 k €	-59.7%	5,1 k €	+4.0%	4,9 k €	-26.4%	6,7 k €	-18.3%	8,2 k €	-78.0%	37,2 k €
Balance sheet
Equity	586,7 k €	+36.5%	429,8 k €	+18.0%	364,2 k €	+399%	72,9 k €	-74.2%	282,7 k €	+5.0%	269,4 k €	-68.5%	854,2 k €	+37.0%	623,6 k €	+4.2%	598,5 k €	-3.5%	619,9 k €	+2.4%	605,1 k €	+1.9%	594,1 k €	+0.3%	592,1 k €	+0.3%	590 k €	+0.9%	584,9 k €	+0.8%	580 k €	+1.2%	573,3 k €	+1.4%	565,1 k €
Total assets	4,8 M €	+45.4%	3,3 M €	+26.8%	2,6 M €	+0.7%	2,6 M €	-17.7%	3,2 M €	-17.5%	3,8 M €	-20.6%	4,8 M €	+81.6%	2,7 M €	-5.9%	2,8 M €	-28.2%	3,9 M €	+51.9%	2,6 M €	+17.7%	2,2 M €	-16.1%	2,6 M €	-0.5%	2,6 M €	+65.0%	1,6 M €	+8.4%	1,5 M €	+6.0%	1,4 M €	+68.7%	827,8 k €
Cash	187,6 k €	-19.7%	233,5 k €	-6.7%	250,2 k €	-73.5%	944,2 k €	+315%	227,4 k €	-79.1%	1,1 M €	-53.8%	2,4 M €	+347%	527,3 k €	-39.6%	872,4 k €	+100%	435,5 k €	+711%	53,7 k €	+294%	13,6 k €	-88.9%	122,3 k €	-30.0%	174,8 k €	+115%	81,3 k €	+145%	33,2 k €	-69.0%	107,2 k €	-63.8%	296,3 k €
Debts	4,2 M €	+46.2%	2,9 M €	+28.6%	2,3 M €	-11.1%	2,5 M €	-12.2%	2,9 M €	-19.2%	3,6 M €	-10.3%	4 M €	+101%	2 M €	-11.3%	2,2 M €	-32.8%	3,3 M €	+66.9%	2 M €	+23.5%	1,6 M €	-20.9%	2 M €	-0.8%	2,1 M €	+102%	1 M €	+13.2%	900,1 k €	+9.4%	823 k €	+213%	262,7 k €
Other
Workforce	14,6 ETP	-24.4%	19,3 ETP	-3.0%	19,9 ETP	+16.4%	17,1 ETP	+3.6%	16,5 ETP	+0.6%	16,4 ETP	+23.3%	13,3 ETP	-2.9%	13,7 ETP	+17.1%	11,7 ETP	+4.5%	11,2 ETP	-1.8%	11,4 ETP	+21.3%	9,4 ETP	+17.5%	8,0 ETP	-3.6%	8,3 ETP	0.0%	8,3 ETP	+13.7%	7,3 ETP	+52.1%	4,8 ETP	+17.1%	4,1 ETP

Estimate

Indicative valuation

As an indication, this company is worth

between 1 M€ and 2,5 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2024 · 1 active · 21 ended

Active mandates

Advanced incubation platform

Director · since 29 décembre 2020 · 0434.710.448

Represented by Hugo VAN HEUVERSWYN

Active

Ended mandates

Advanced incubation platform

Director · since 29 décembre 2020 · 0434.710.448

Represented by Hugo VAN HEUVERSWYN

Ended

Advanced incubation platform

Managing director · since 29 décembre 2020 · until 29 décembre 2026 · 0434.710.448

Represented by Hugo Van Heuverswyn

Ended

Advanced incubation platform

Managing director · since 15 janvier 2016 · until 29 juin 2021 · 0434.710.448

Represented by Hugo Van Heuverswyn

Ended

Advanced incubation platform

Managing director · since 15 janvier 2016 · until 29 juin 2021 · 0434.710.448

Represented by Hugo Van Heuverswyn

Ended

At this address

Other companies at this address

Company	CBE no.
123inkt.be● Active	0832.574.952
Advanced incubation platform● Active	0434.710.448
GROUP AIP● Active	0647.810.144
INTEGRA CAPITAL PARTNERS● Active	0711.710.477
Integra Fund● Active	0712.606.441
Integra Fund III● Active	1020.502.653
Integra Fund III A Privak● Active	1019.470.295
Integra Fund III B Privak● Active	1019.465.842
Integra Fund III Investco● Active	1030.555.516
Integra Fund III Maatschap● Active	1029.738.142
Integra Fund Investco● Active	1014.992.855
INTEGRA FUND MAATSCHAP● Active	1014.641.576
INTEGRA FUND PRIVAK● Active	0711.957.531
Integra Global Fund● Active	0783.993.986
Integra Global Fund Privak● Active	0783.949.149
Integra Global Investco● Active	1015.909.011
Integra Global Maatschap● Active	0793.628.660
Integra Partners● Active	0782.277.086
Maatschap Maes Integra● Active	0760.809.602
STAPLES BELGIUM● Bankrupt	0465.406.592

Annual accounts

Full financial information

	2024	2023	2022	2021	2020	2019
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019
Closing of the financial year	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	21/08/2025	29/08/2024	28/06/2023	28/11/2022	30/11/2021	27/11/2020
General meeting	30/06/2025	25/06/2024	27/06/2023	31/10/2022	28/10/2021	17/11/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

19 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2024	30/06/2025	21/08/2025	Dutch	PDF
Abridged model	31/12/2023	25/06/2024	29/08/2024	Dutch	PDF
Abridged model	31/12/2022	27/06/2023	28/06/2023	Dutch	PDF
Abridged model	31/12/2021	31/10/2022	28/11/2022	Dutch	PDF
Abridged model	31/12/2020	28/10/2021	30/11/2021	Dutch	PDF
Abridged model	31/12/2019	17/11/2020	27/11/2020	Dutch	PDF
Abridged model	31/12/2018	20/12/2019	30/12/2019	Dutch	PDF
Abridged model	31/12/2017	26/06/2018	09/10/2018	Dutch	PDF
Abridged model	31/12/2016	31/07/2017	31/08/2017	Dutch	PDF
Abridged model	31/12/2015	30/09/2016	05/10/2016	Dutch	PDF
Abridged model	30/09/2014	27/10/2015	28/10/2015	Dutch	PDF
Abridged model	30/09/2013	31/03/2014	15/04/2014	Dutch	PDF
Abridged model	30/09/2012	17/01/2013	30/04/2013	Dutch	PDF
Abridged model	30/09/2011	20/01/2012	30/03/2012	Dutch	PDF
Abridged model	30/09/2010	21/01/2011	08/04/2011	Dutch	PDF
Abridged model	30/09/2009	15/01/2010	29/04/2010	Dutch	PDF
Abridged model	30/09/2008	16/01/2009	27/02/2009	Dutch	PDF
Abridged model	30/09/2007	18/01/2008	30/05/2008	Dutch	PDF
Abridged model	30/09/2006	19/01/2007	31/05/2007	Dutch	PDF

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 1 M€ and 2,5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 1 active · 21 ended

Active mandates

Advanced incubation platform

Director · since 29 décembre 2020 · 0434.710.448

Represented by Hugo VAN HEUVERSWYN

Active

Ended mandates

Advanced incubation platform

Director · since 29 décembre 2020 · 0434.710.448

Represented by Hugo VAN HEUVERSWYN

Ended

Advanced incubation platform

Managing director · since 29 décembre 2020 · until 29 décembre 2026 · 0434.710.448

Represented by Hugo Van Heuverswyn

Ended

Advanced incubation platform

Managing director · since 15 janvier 2016 · until 29 juin 2021 · 0434.710.448

Represented by Hugo Van Heuverswyn

Ended

Advanced incubation platform

Managing director · since 15 janvier 2016 · until 29 juin 2021 · 0434.710.448

Represented by Hugo Van Heuverswyn

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates11/01/2021
ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates16/10/2015
ONTSLAGEN - BENOEMINGEN - BOEKJAAR - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Registered office25/04/2014
MAATSCHAPPELIJKE ZETEL
PDF
Mandates04/10/2010
ONTSLAGEN - BENOEMINGEN
PDF
Mandates12/05/2010
ONTSLAGEN - BENOEMINGEN
PDF
Mandates19/04/2010
ONTSLAGEN - BENOEMINGEN
PDF
Mandates24/03/2006
ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING - KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates11/05/2005
ONTSLAGEN - BENOEMINGEN
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2024
Annual accounts 2024157 k €↑
2023
Annual accounts 202365,5 k €↓
2022
Annual accounts 2022291,3 k €↑
2021
Annual accounts 2021-209,8 k €↓
2020
Annual accounts 202013,4 k €↑
2019
Annual accounts 2019-584,9 k €↓
2018
Annual accounts 2018230,7 k €↑
2017
Annual accounts 201725,1 k €↑
2016
Annual accounts 2016-21,5 k €↓
2015
Annual accounts 201514,8 k €↑
2014
Annual accounts 201411 k €↑
2013
Annual accounts 20132 k €↓
2012
Annual accounts 20122,1 k €↓
2011
Annual accounts 20115,1 k €↑
2010
Annual accounts 20104,9 k €↓
2009
Annual accounts 20096,7 k €↓
2008
Annual accounts 20088,2 k €↓
2007
Annual accounts 200737,2 k €
13/08/2001
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL

Overview

What does BIOMEDICAL APPLICATION OF RESEARCH IN INFECTIOUS DISEASES CONTROL do?

Trend over 18 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline